Cogstate (ASX:CGS) YoY EBITDA Growth: -3.28% (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ASX:CGS Cogstate Ltd ASX:CGS
78 GF Score
Price A$2.50
GF Value A$2.09
Valuation Modestly Overvalued
View Full Analysis

What is Cogstate YoY EBITDA Growth?

Cogstate ASX:CGS -0.79% 78 YoY EBITDA Growth is -3.28% as of Dec. 2025. GuruFocus rates ASX:CGS with a GF Score™ of 78/100 and a GF Value™ of A$2.09 (Modestly Overvalued).

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months. Cogstate's YoY EBITDA Growth for the quarter that ended in Dec. 2025 was -3.28%.

Cogstate's EBITDA per Share for the six months ended in Dec. 2025 was A$0.06.

Cogstate YoY EBITDA Growth Historical Data

* Premium members only.

The historical data trend for Cogstate's YoY EBITDA Growth can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Cogstate YoY EBITDA Growth Chart

Cogstate Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
YoY EBITDA Growth
Get a 7-Day Free Trial Premium Member Only Premium Member Only 6,100.00 69.35 -54.29 79.17 73.26

Cogstate Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
YoY EBITDA Growth Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 130.77 71.88 103.33 63.64 -3.28
ASX:CGS
78GF Score
Cogstate Ltd ASX:CGS
YoY EBITDA Growth is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Cogstate YoY EBITDA Growth Calculation

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months.

Cogstate's YoY EBITDA Growth for the fiscal year that ended in Jun. 2025 is calculated as:

YoY EBITDA Growth (A: Jun. 2025 )
=(EBITDA per Share (A: Jun. 2025 )-EBITDA per Share (A: Jun. 2024 ))/ | EBITDA per Share (A: Jun. 2024 ) |
=(0.149-0.086)/ | 0.086 |
=73.26 %

Cogstate's YoY EBITDA Growth for the quarter that ended in Dec. 2025 is calculated as:

YoY EBITDA Growth (Q: Dec. 2025 )
=(EBITDA per Share (Q: Dec. 2025 )-EBITDA per Share (Q: Dec. 2024 )) / | EBITDA per Share (Q: Dec. 2024 )) |
=(0.059-0.061)/ | 0.061 |
=-3.28 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about YoY EBITDA Growth →
What does a YoY EBITDA Growth of -3.28% mean?
Cogstate (ASX:CGS) has a YoY EBITDA Growth of -3.28% as of Dec. 2025. YoY EBITDA Growth is the percentage change of EBITDA per share over the past 12-month. View historical data for Cogstate and its competitors.
Is Cogstate's YoY EBITDA Growth too high?
Cogstate's current YoY EBITDA Growth is -3.28%. Overall, Cogstate has a GF Score™ of 78/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Cogstate's YoY EBITDA Growth compare to VEEV and BTSG?
Cogstate's YoY EBITDA Growth of -3.28% can be compared against companies in the Healthcare Providers & Services industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good YoY EBITDA Growth for a Healthcare Providers & Services company?
A good YoY EBITDA Growth depends on the Healthcare Providers & Services industry context. However, YoY EBITDA Growth should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high YoY EBITDA Growth mean?
A high YoY EBITDA Growth can signal that a stock is expensive relative to its fundamentals. YoY EBITDA Growth is the percentage change of EBITDA per share over the past 12-month. View historical data for Cogstate and its competitors. Cogstate's current YoY EBITDA Growth is -3.28%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cogstate stock overvalued right now?
Based on GuruFocus' analysis, Cogstate (ASX:CGS) is currently considered Modestly Overvalued. The stock's GF Value™ is A$2.09, compared to a current price of A$2.50 — trading 19.6% above its estimated fair value. The current YoY EBITDA Growth is -3.28%. Cogstate's overall GF Score™ is 78/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is YoY EBITDA Growth calculated?
YoY EBITDA Growth is calculated from a company's financial statements. For Cogstate (ASX:CGS), the current YoY EBITDA Growth is -3.28% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Cogstate (ASX:CGS) Overvalued in 2026?

Based on GuruFocus' analysis, Cogstate stock appears to be overvalued. The current stock price of A$2.50 is trading 19.6% above its estimated GF Value™ of A$2.09. GuruFocus considers Cogstate to be Modestly Overvalued.

Key valuation signals for ASX:CGS:

  • YoY EBITDA Growth: -3.28%
  • GF Value™: A$2.09 vs. price of A$2.50 (19.6% above fair value)
  • GF Score™: 78/100

No single metric tells the full story. See the ASX:CGS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Cogstate Business Description

Other Exchanges COGZF:USAC4B:Germany
Address 367 Collins Street, Level 32, Melbourne, VIC, AUS, 3000
Cogstate Ltd is a cognitive science company. The principal activity of the group is the Creation, validation, and commercialisation of digital brain health assessments; and the Design and provision of quality assurance services in clinical trials, focused on the administration, scoring, and recording of conventional brain health assessments and reporting. Its operating segment includes Clinical Trials, Healthcare, and Administration. The company generates maximum revenue from the Clinical Trials segment. In the clinical trials segment, technology and services are sold to pharmaceutical and biotechnology companies. The company derives revenue from the sale of licensed software and cognitive testing services.
78GF Score

Get the complete analysis for ASX:CGS

YoY EBITDA Growth is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

A$2.50
Price
A$2.09
GF Value